DTC marketing will evolve into a conversation, CEO says

04/23/2012 | Chief Marketer

Direct-to-consumer drug advertising is changing from a linear channel to a conversation that engages patients, although government regulations place some limits on that evolution, says Jay Bolling, CEO of Roska Healthcare. "What you’ll see is an evolution toward multichannel consumer engagement ... across the entire range of the patient journey, from risk assessment, through diagnosis, product trial, and ultimately, brand advocacy based on successful outcomes," he said.

View Full Article in:

Chief Marketer

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC